CA1100871A - Labelled phospholipid spheres for organ visualization - Google Patents
Labelled phospholipid spheres for organ visualizationInfo
- Publication number
- CA1100871A CA1100871A CA241,628A CA241628A CA1100871A CA 1100871 A CA1100871 A CA 1100871A CA 241628 A CA241628 A CA 241628A CA 1100871 A CA1100871 A CA 1100871A
- Authority
- CA
- Canada
- Prior art keywords
- agent
- 99mtc
- scanning
- pls
- labelled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 28
- 210000000056 organ Anatomy 0.000 title claims abstract description 17
- 238000012800 visualization Methods 0.000 title abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 102
- 210000004072 lung Anatomy 0.000 claims abstract description 47
- 210000004185 liver Anatomy 0.000 claims abstract description 41
- 239000000463 material Substances 0.000 claims abstract description 38
- 230000004931 aggregating effect Effects 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 32
- 238000002360 preparation method Methods 0.000 claims abstract description 30
- 238000002347 injection Methods 0.000 claims abstract description 18
- 239000007924 injection Substances 0.000 claims abstract description 18
- 230000004807 localization Effects 0.000 claims description 29
- 239000002245 particle Substances 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 20
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 15
- 239000001110 calcium chloride Substances 0.000 claims description 15
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 150000002500 ions Chemical class 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 230000009467 reduction Effects 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 8
- 150000001768 cations Chemical class 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000004227 calcium gluconate Substances 0.000 claims description 7
- 235000013927 calcium gluconate Nutrition 0.000 claims description 7
- 229960004494 calcium gluconate Drugs 0.000 claims description 7
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 7
- 230000002829 reductive effect Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 125000002091 cationic group Chemical group 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 230000000536 complexating effect Effects 0.000 claims description 5
- 238000006386 neutralization reaction Methods 0.000 claims description 5
- ZOKXTWBITQBERF-AKLPVKDBSA-N Molybdenum Mo-99 Chemical compound [99Mo] ZOKXTWBITQBERF-AKLPVKDBSA-N 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 230000003139 buffering effect Effects 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229950009740 molybdenum mo-99 Drugs 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 2
- 150000003839 salts Chemical group 0.000 claims description 2
- 238000001246 colloidal dispersion Methods 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 239000012736 aqueous medium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 238000002372 labelling Methods 0.000 abstract description 11
- 230000000694 effects Effects 0.000 description 24
- 235000011148 calcium chloride Nutrition 0.000 description 13
- 239000000725 suspension Substances 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 238000009826 distribution Methods 0.000 description 10
- 229940028435 intralipid Drugs 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 238000010171 animal model Methods 0.000 description 9
- 239000012876 carrier material Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 229940050410 gluconate Drugs 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 239000012798 spherical particle Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000008344 egg yolk phospholipid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 101100335313 Mus musculus Foxf2 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 150000008103 phosphatidic acids Chemical class 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004088 pulmonary circulation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052713 technetium Inorganic materials 0.000 description 1
- GKLVYJBZJHMRIY-UHFFFAOYSA-N technetium atom Chemical compound [Tc] GKLVYJBZJHMRIY-UHFFFAOYSA-N 0.000 description 1
- IUTCEZPPWBHGIX-UHFFFAOYSA-N tin(2+) Chemical compound [Sn+2] IUTCEZPPWBHGIX-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
- A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
- A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US539,134 | 1975-01-07 | ||
| US05/539,134 US3992513A (en) | 1975-01-07 | 1975-01-07 | Labelled phospholipid material colloidially dispersed and sized to localize at preselected organs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1100871A true CA1100871A (en) | 1981-05-12 |
Family
ID=24149936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA241,628A Expired CA1100871A (en) | 1975-01-07 | 1975-12-12 | Labelled phospholipid spheres for organ visualization |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US3992513A (OSRAM) |
| CA (1) | CA1100871A (OSRAM) |
| DE (1) | DE2600311A1 (OSRAM) |
| FR (1) | FR2297034A1 (OSRAM) |
| GB (1) | GB1503461A (OSRAM) |
| NL (1) | NL7600104A (OSRAM) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4070493A (en) * | 1977-03-16 | 1978-01-24 | Merck & Co., Inc. | Diagnostic kit |
| US4310506A (en) * | 1979-02-22 | 1982-01-12 | California Institute Of Technology | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species |
| US4310505A (en) * | 1979-11-08 | 1982-01-12 | California Institute Of Technology | Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances |
| US4489054A (en) * | 1980-04-18 | 1984-12-18 | Research Corporation | Cationic lipophilic complexes of 99m Tc and their use for myocardial and hepatobiliary imaging |
| US4387087A (en) * | 1980-04-18 | 1983-06-07 | Research Corporation | Cationic lipophilic complexes of 99m Tc and their use for myocardial and hepatobiliary imaging |
| US4406876A (en) * | 1980-10-14 | 1983-09-27 | Research Foundation Of The State Univ. Of New York | Sulfur free small-particle production of technetium sulfur colloid |
| NL8320128A (nl) * | 1982-03-25 | 1984-02-01 | Syntex Inc | Werkwijze en inrichting voor de diagnose van ademhalingsziekten en allergieen. |
| US5435989A (en) | 1982-03-30 | 1995-07-25 | Vestar, Inc. | Method of targeting a specific location in a body |
| US5441745A (en) * | 1982-03-30 | 1995-08-15 | Vestar, Inc. | Method of delivering micellular particles encapsulating chemotherapeutic agents to tumors in a body |
| GB8310038D0 (en) * | 1983-04-13 | 1983-05-18 | Amersham Int Plc | Technetium-99 labelled tin colloid |
| US5019369A (en) * | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| IE58124B1 (en) * | 1984-11-23 | 1993-07-14 | Vestar Inc | The use of micellular particles for making compositions for targeting tumors in humans |
| US4877619A (en) * | 1986-08-25 | 1989-10-31 | Vestar, Inc. | Liposomal vesicles for intraperitoneal administration of therapeutic agents |
| US5328678A (en) * | 1987-11-04 | 1994-07-12 | Vestar, Inc. | Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy |
| CA1314209C (en) * | 1987-11-04 | 1993-03-09 | Gary Fujii | Composition and method for use for liposome encapsulated compounds for neutron capture tumor therapy |
| BR9201168A (pt) * | 1992-04-02 | 1994-04-12 | Zerbini E J Fundacao | Microemulsoes usadas como velculo para carregar quimioterapicos as celulas neoplasicas |
| US5874059A (en) * | 1992-04-02 | 1999-02-23 | Fundacao E.J. Zerbini | Microemulsions labelled with radioactivity used as means for targeting neoplastic cells |
| US5851510A (en) * | 1994-05-16 | 1998-12-22 | The Board Of Regents Of The University Of Michigan | Hepatocyte-selective oil-in-water emulsion |
| US5607653A (en) * | 1995-03-17 | 1997-03-04 | Mainstream Engineering Corporation | Process and apparatus for oxidizing and neutralizing caustic waste to liquid fertilizer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3663685A (en) * | 1968-04-01 | 1972-05-16 | Minnesota Mining & Mfg | Biodegradable radioactive particles |
| US3597455A (en) * | 1969-05-29 | 1971-08-03 | Squibb & Sons Inc | Process for manufacture of sterile lecithin |
| BE786566A (fr) * | 1971-07-20 | 1973-01-22 | Squibb & Sons Inc | Agregats a base de tc-99m et d'albumine |
| US3863004A (en) * | 1972-03-20 | 1975-01-28 | Mallinckrodt Chemical Works | Denatured macroprotein with divalent tin for tagging with technetium-99m and method of preparation |
-
1975
- 1975-01-07 US US05/539,134 patent/US3992513A/en not_active Expired - Lifetime
- 1975-12-12 CA CA241,628A patent/CA1100871A/en not_active Expired
-
1976
- 1976-01-06 GB GB294/76A patent/GB1503461A/en not_active Expired
- 1976-01-07 FR FR7600251A patent/FR2297034A1/fr active Granted
- 1976-01-07 DE DE19762600311 patent/DE2600311A1/de active Pending
- 1976-01-07 NL NL7600104A patent/NL7600104A/xx not_active Application Discontinuation
- 1976-05-12 US US05/685,587 patent/US4086330A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| NL7600104A (nl) | 1976-07-09 |
| GB1503461A (en) | 1978-03-08 |
| US4086330A (en) | 1978-04-25 |
| FR2297034A1 (fr) | 1976-08-06 |
| US3992513A (en) | 1976-11-16 |
| FR2297034B1 (OSRAM) | 1978-11-03 |
| DE2600311A1 (de) | 1976-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1100871A (en) | Labelled phospholipid spheres for organ visualization | |
| US4510125A (en) | Process for making lyophilized radiographic imaging kit | |
| Gabizon et al. | An improved method for in vivo tracing and imaging of liposomes using a gallium 67-deferoxamine complex | |
| US4310506A (en) | Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species | |
| Eckelman et al. | Radiopharmaceuticals labelled with technetium | |
| US5158760A (en) | 99m TC labeled liposomes | |
| AU656915B2 (en) | Stabilized therapeutic radiopharmaceutical complexes | |
| US3987157A (en) | Technetium 99-m labeled radio-diagnostic agents employing stannous tartrate and method of preparation | |
| US4707353A (en) | Radiographic imaging agents | |
| US5143713A (en) | 99m Tc labeled liposomes | |
| US3803299A (en) | Method of producing a diagnostic preparation on the basis of macro-aggregates of serum albumin labelled with | |
| Hwang | The use of gamma ray perturbed angular correlation technique for the study of liposomal integrity in vitro and in vivo | |
| Ogihara-Umeda et al. | Optimal radiolabeled liposomes for tumor imaging | |
| CA1215372A (en) | Radioactive chelate complexes containing pyridine-n-oxides | |
| US5328678A (en) | Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy | |
| US4042677A (en) | Technetium-99m labeled radiodiagnostic agents and method of preparation | |
| EP0169232B1 (en) | Composition for technetium-99m labelling of proteinaceous material | |
| US4187285A (en) | Microaggregated albumin | |
| Barratt et al. | The labeling of liposomal membranes with radioactive technetium | |
| JP2710847B2 (ja) | 中性子捕獲療法剤およびその製法 | |
| Soloway et al. | Survey of radiopharmaceuticals and their current status | |
| EP0111414A2 (en) | Radiographic imaging agents | |
| Thakur | Radioactive compounds of Gallium and Indium | |
| Dunnick et al. | Studies of radiopharmaceutical-enclosing lipid-protein vesicles formed from native plasma components | |
| Noronha et al. | Factors affecting the preparation of 99mTc-sulfur colloid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |